Andrew D Meyer1,2, Anjana R Rishmawi1, Robin Kamucheka2, Crystal Lafleur2, Andriy I Batchinsky3, Nigel Mackman4, Andrew P Cap2. 1. Division of Pediatric Critical Care, Department of Pediatrics, University of Texas Health, San Antonio, Texas. 2. Coagulation and Blood Research, U.S. Army Institute of Surgical Research (USAISR), Ft. Sam Houston, Texas. 3. Extracorporeal Life Support, U.S. Army Institute of Surgical Research (USAISR), Ft. Sam Houston, Texas. 4. Thrombosis and Hemostasis Program, Division of Hematology and Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Abstract
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has frequent and sometimes lethal thrombotic complications. The role that activated platelets, leukocytes, and small (0.3-micron to 1-micron) extracellular vesicles (EVs) play in ECMO thrombosis is not well understood. OBJECTIVES: To test the effect of blood flow rate on the generation of activated platelets, leukocytes, and EVs in a simulated neonatal ECMO circuit using heparinized human whole blood. METHODS: Simulated neonatal roller pump circuits circulated whole blood at low, nominal, and high flow rates (0.3, 0.5, and 0.7 L/min) for 6 h. Coagulopathy was defined by thromboelastography (TEG), STA® -procoagulant phospholipid clot time (STA®- Procoag-PPL), and calibrated automated thrombogram. High-resolution flow cytometry measured the cellular expression of prothrombotic phospholipids and proteins on platelets, leukocytes, and EV. RESULTS: Despite heparinization, occlusive thrombosis halted flow in two of five circuits at 0.3 L/min and three of five circuits at 0.7 L/min. None of the five circuits at 0.5 L/min exhibited occlusive thrombosis. Phosphatidylserine (PS)-positive platelets and EVs increased at all flow rates more than blood under static conditions (P < .0002). Tissue factor (TF)-positive leukocytes and EVs increased only in low-flow and high-flow circuits (P < .0001). Tissue factor pathway inhibitor (TFPI), at 50 times more than the concentration in healthy adults, failed to suppress thrombin initiation in low-flow and high-flow circuits. CONCLUSIONS: This in vitro study informs ECMO specialists to avoid low and high blood flow that increases TF expression on leukocytes and EVs, which likely initiate clot formation. Interventions to decrease TF generated by ECMO may be an effective approach to decrease thrombosis.
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) has frequent and sometimes lethal thrombotic complications. The role that activated platelets, leukocytes, and small (0.3-micron to 1-micron) extracellular vesicles (EVs) play in ECMO thrombosis is not well understood. OBJECTIVES: To test the effect of blood flow rate on the generation of activated platelets, leukocytes, and EVs in a simulated neonatal ECMO circuit using heparinized human whole blood. METHODS: Simulated neonatal roller pump circuits circulated whole blood at low, nominal, and high flow rates (0.3, 0.5, and 0.7 L/min) for 6 h. Coagulopathy was defined by thromboelastography (TEG), STA® -procoagulant phospholipid clot time (STA®- Procoag-PPL), and calibrated automated thrombogram. High-resolution flow cytometry measured the cellular expression of prothrombotic phospholipids and proteins on platelets, leukocytes, and EV. RESULTS: Despite heparinization, occlusive thrombosis halted flow in two of five circuits at 0.3 L/min and three of five circuits at 0.7 L/min. None of the five circuits at 0.5 L/min exhibited occlusive thrombosis. Phosphatidylserine (PS)-positive platelets and EVs increased at all flow rates more than blood under static conditions (P < .0002). Tissue factor (TF)-positive leukocytes and EVs increased only in low-flow and high-flow circuits (P < .0001). Tissue factor pathway inhibitor (TFPI), at 50 times more than the concentration in healthy adults, failed to suppress thrombin initiation in low-flow and high-flow circuits. CONCLUSIONS: This in vitro study informs ECMO specialists to avoid low and high blood flow that increases TF expression on leukocytes and EVs, which likely initiate clot formation. Interventions to decrease TF generated by ECMO may be an effective approach to decrease thrombosis.
Authors: Jan Van Deun; Pieter Mestdagh; Patrizia Agostinis; Özden Akay; Sushma Anand; Jasper Anckaert; Zoraida Andreu Martinez; Tine Baetens; Els Beghein; Laurence Bertier; Geert Berx; Janneke Boere; Stephanie Boukouris; Michel Bremer; Dominik Buschmann; James B Byrd; Clara Casert; Lesley Cheng; Anna Cmoch; Delphine Daveloose; Eva De Smedt; Seyma Demirsoy; Victoria Depoorter; Bert Dhondt; Tom A P Driedonks; Aleksandra Dudek; Abdou Elsharawy; Ilaria Floris; Andrew D Foers; Kathrin Gärtner; Abhishek D Garg; Edward Geeurickx; Jan Gettemans; Farzaneh Ghazavi; Bernd Giebel; Tom Groot Kormelink; Grace Hancock; Hetty Helsmoortel; Andrew F Hill; Vincent Hyenne; Hina Kalra; David Kim; Joanna Kowal; Sandra Kraemer; Petra Leidinger; Carina Leonelli; Yaxuan Liang; Lien Lippens; Shu Liu; Alessandra Lo Cicero; Shaun Martin; Suresh Mathivanan; Prabhu Mathiyalagan; Támas Matusek; Gloria Milani; Marta Monguió-Tortajada; Liselot M Mus; Dillon C Muth; Andrea Németh; Esther N M Nolte-'t Hoen; Lorraine O'Driscoll; Roberta Palmulli; Michael W Pfaffl; Bjarke Primdal-Bengtson; Erminia Romano; Quentin Rousseau; Susmita Sahoo; Natalia Sampaio; Monisha Samuel; Benjamin Scicluna; Bieke Soen; Anneleen Steels; Johannes V Swinnen; Maarit Takatalo; Safia Thaminy; Clotilde Théry; Joeri Tulkens; Isabel Van Audenhove; Susanne van der Grein; Alan Van Goethem; Martijn J van Herwijnen; Guillaume Van Niel; Nadine Van Roy; Alexander R Van Vliet; Niels Vandamme; Suzanne Vanhauwaert; Glenn Vergauwen; Frederik Verweij; Annelynn Wallaert; Marca Wauben; Kenneth W Witwer; Marijke I Zonneveld; Olivier De Wever; Jo Vandesompele; An Hendrix Journal: Nat Methods Date: 2017-02-28 Impact factor: 28.547
Authors: Dylan Burger; Sarah Schock; Charlie S Thompson; Augusto C Montezano; Antoine M Hakim; Rhian M Touyz Journal: Clin Sci (Lond) Date: 2013-04 Impact factor: 6.124
Authors: E Biró; K N Sturk-Maquelin; G M T Vogel; D G Meuleman; M J Smit; C E Hack; A Sturk; R Nieuwland Journal: J Thromb Haemost Date: 2003-12 Impact factor: 5.824
Authors: Katherine Irby; Christopher Swearingen; Jonathan Byrnes; Joshua Bryant; Parthak Prodhan; Richard Fiser Journal: Pediatr Crit Care Med Date: 2014-05 Impact factor: 3.624
Authors: Sven R Olson; Catherine R Murphree; David Zonies; Andrew D Meyer; Owen J T Mccarty; Thomas G Deloughery; Joseph J Shatzel Journal: ASAIO J Date: 2021-03-01 Impact factor: 3.826
Authors: Meredith A Achey; Uttara P Nag; Victoria L Robinson; Christopher R Reed; Gowthami M Arepally; Jerrold H Levy; Elisabeth T Tracy Journal: Clin Appl Thromb Hemost Date: 2020 Jan-Dec Impact factor: 2.389
Authors: Katrina K Ki; Jonathan E Millar; Daman Langguth; Margaret R Passmore; Charles I McDonald; Kiran Shekar; Manu Shankar-Hari; Hwa Jin Cho; Jacky Y Suen; John F Fraser Journal: Front Immunol Date: 2021-01-08 Impact factor: 7.561
Authors: Peng Fang; Jianjun Du; Andrea Boraschi; Silvia Bozzi; Alberto Redaelli; Marianne Schmid Daners; Vartan Kurtcuoglu; Filippo Consolo; Diane de Zélicourt Journal: Front Cardiovasc Med Date: 2022-03-11
Authors: Nikolaus B Binder; François Depasse; Julia Mueller; Thomas Wissel; Stephan Schwers; Matthias Germer; Björn Hermes; Peter L Turecek Journal: J Thromb Haemost Date: 2021-10-08 Impact factor: 16.036
Authors: Senna Staessens; Mouhamed D Moussa; Adeline Pierache; Antoine Rauch; Natacha Rousse; Eric Boulleaux; Alexandre Ung; Linda Desender; Bénédicte Pradines; André Vincentelli; Olaf Mercier; Julien Labreuche; Alain Duhamel; Eric Van Belle; Flavien Vincent; Annabelle Dupont; Karen Vanhoorelbeke; Delphine Corseaux; Simon F De Meyer; Sophie Susen Journal: J Thromb Haemost Date: 2022-07-03 Impact factor: 16.036